PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3986.96%
Revenue growth above 1.5x AGEN's 28.03%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
804.39%
Gross profit growth above 1.5x AGEN's 50.03%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
35.83%
EBIT growth 1.25-1.5x AGEN's 30.63%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
35.83%
Operating income growth similar to AGEN's 34.36%. Walter Schloss would assume both share comparable operational structures.
36.40%
Net income growth above 1.5x AGEN's 3.12%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
37.84%
EPS growth above 1.5x AGEN's 3.16%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
37.84%
Diluted EPS growth above 1.5x AGEN's 2.58%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.81%
Slight or no buybacks while AGEN is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
2.81%
Slight or no buyback while AGEN is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-14.43%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-14.57%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1885.22%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.95%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
81.42%
Positive 3Y OCF/share CAGR while AGEN is negative. John Neff might see a big short-term edge in operational efficiency.
-991.23%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
94.68%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
84.15%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
1611.09%
10Y equity/share CAGR above 1.5x AGEN's 267.67%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-55.02%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
127.30%
3Y equity/share CAGR 1.25-1.5x AGEN's 108.06%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.96%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-36.45%
We’re deleveraging while AGEN stands at 10.34%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-19.33%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-34.65%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.